Sunday, May 4, 2008

Cervical cancer screening needs improvement


Ivanhoe, FL
Screening women for cervical cancer pays off with a reduced risk of developing the cancer, but room for improvement still exists in screening programs and methods.

In a study based on data from Swedish registries, researchers found women who failed to have a Pap smear within the recommended three year time frame were 2.5 times more likely to be diagnosed with the disease and five times more likely to have advanced cancer than women who were screened on time. A Pap smear can identify pre-cancerous cells, leading to early treatment and prevention of cervical cancer.

Still, women found to have abnormal Pap results remained at increased risk for developing cervical cancer. Overall, about 11 percent of all the cases identified in the study occurred in women who had abnormal Pap smears, and these women were more than seven times more likely to be diagnosed with the disease than those with normal results. Improper follow up -- such as not ordering a biopsy for women with abnormal results -- figured into the risk.

The authors say they believe the study points out the need to step-up efforts to ensure all women are screened for cervical cancer and ensure women with abnormal results receive the proper follow up care.

Labels:

 Subscribe to Cervical Cancer News Information Links

Sunday, April 27, 2008

ThinPrep Pap Test and imaging system, cervical cancer screening


Chillicothe, Ohio

New equipment to provide earlier, more accurate cervical cancer diagnosis
Adena Health System Wednesday began use of a new, advanced cervical cancer screening system that is designed to improve efficiency and performance of the screening process.

The new ThinPrep Imaging System is the first fully integrated, interactive computer system to assist lab professionals in the primary screening of ThinPrep Pap Test slides. The system combines revolutionary imaging technology with medical experts' ability to interpret the results to improve cervical cancer screening efficiency and performance.

"Adena Regional Medical Center is committed to providing our patients with the most advanced technology to detect disease early, and the ThinPrep System enables us to do that," said Dr. Byron Smith, pathologist at Adena. "Using this system offers significant improvements over previous screening technologies. Making this technology the standard in our practice was simply the right thing to do."
The ThinPrep Pap Test is a liquid-based test that uses a fluid medium to collect and preserve cervical cells. Specimens are first collected by the clinician with a cervical sampling device in the same way as is done now. Instead of smearing the cells on a slide, however, the device is rinsed into a ThinPrep vial containing a fluid that captures virtually all of the cells. The specimen is then sent to the laboratory where a ThinPrep Processor eliminates debris and distributes a uniform, representative thin-layer of cells on a microscope slide. The ThinPrep System improves the quality of the specimen, which can result in more accurate diagnoses and fewer unnecessary repeat tests.

According to the National Cancer Institute, about 15,000 women in the United States are diagnosed with cervical cancer each year and about 5,000 die of the disease. Cervical cancer is almost completely curable if detected early.

More than 30 published studies with more than 500,000 patients have demonstrated the improved performance of the ThinPrep system when compared to the conventional Pap smear. A study published in the American Journal of Obstetrics and Gynecologyconcluded that the ThinPrep improves diagnosis of low-grade and high-grade precancerous cell abnormalities compared to the conventional Pap smear. The article also demonstrated improved sample adequacy. Currently, about 70 percent of all Pap tests in the U.S. utilize the ThinPrep Pap Test.

Labels: ,

 Subscribe to Cervical Cancer News Information Links

Sunday, April 20, 2008

Cancer prevention advocates fight New Hamopshire budget cuts


Concord, NH
The American Cancer Society and other groups are asking Gov. John Lynch to preserve funding for smoking cessation and cancer screening programs.

The state had planned to spend $2 million on the programs, but that total was trimmed to $250,000 as part of the governor's broad budget cuts. The cancer society is fighting back with ads arguing that this is no time to retreat in the fight against cancer.

The bulk of the money was supposed to be used for tobacco prevention and cessation programs. The plan also called for establishing a free colorectal cancer screening program for people with little or no health insurance coverage and expanding a similar screening program for breast and cervical cancers.

Lynch has made $50 million in cuts across the state budget after determining that state revenue would not meet his original budget predictions. Though the cuts affect programs in the 2008 fiscal year, estimates suggest the shortfall for the next fiscal year may be more significant. Advocates are concerned that $4 million funding slated for next year may suffer a similar fate.

"It was a little disheartening to see that what can be given can be taken away really suddenly," said Peter Davies, a spokesman for the cancer society.

A spokesman for Lynch says the governor supports the cancer programs but faced tough choices in trying to balance the books.

"It's a good plan, a good program," said Colin Manning. "It was new money included in the budget, and unfortunately, we're faced with this economic downturn that's impacting revenues."

But Peter Ames, the cancer society's director of government relations, said New Hampshire is going to have to deal with cancer a lot longer than it will deal with a short-term budget shortfall.

"This was really a long-term investment in the state," he said.

Labels: , ,

 Subscribe to Cervical Cancer News Information Links

Friday, April 18, 2008

Gardasil: Dealing cervical cancer a knockout blow


Washington, DC
For the first time, a doctor's arsenal now includes a vaccine that can actually prevent cancer.

Gardasil targets human papillomavirus, or HPV, which causes virtually all cases of cervical cancer and is present in one in four American women.

And health-care providers are beginning to integrate that vaccine into the schedule of other immunizations that children receive during childhood and adolescence.

About 13 million doses of the vaccine have been distributed globally since its approval in June 2006, said Kelley Dougherty, director of public affairs for Merck & Co., the company that created Gardasil. Of those, 10.5 million doses have been distributed in the United States.

"We estimate between 3 to 5 million girls have been vaccinated with Gardasil, but that is a very rough estimate," Dougherty said.

The American Cancer Society estimates that 11,150 new cases of invasive cervical cancer were diagnosed in the United States in 2007, and 3,670 women died from the disease.

Cervical cancer used to be one of the most common causes of cancer death for U.S. women, but the death rate declined by 74 percent between 1955 and 1992. That was largely due to increased use of the Pap test, which can detect cellular changes in the cervix before cancer develops, the cancer society says.

"Women for so many years have heard the message that they need Pap tests, it's almost equivalent to seeing a gynecologist," said Debbie Saslow, director of breast and gynecologic cancers for the American Cancer Society. "I think for breast exams, many women wait for their doctor to recommend it, whereas for the Pap test, they're more likely to go get one."

The death rate from cervical cancer continues to decline by almost 4 percent a year, thanks to the Pap test.

But doctors now believe they are poised to deal cervical cancer a knockout blow, thanks to the HPV vaccine. More >>

Labels: , ,

 Subscribe to Cervical Cancer News Information Links

Monday, April 14, 2008

Harvard Medical School cervical cancer/pap smear Q&A


More On Cervical Cancer/Pap Tests

Answered by Dr. Chris Awtrey, Division of Gynecologic Oncology, Beth Israel Deaconess Medical Center and Dr. Hope Ricciotti, Obstetrician/Gynecologist, The Dimock Center.

Q: What is cervical cancer?

The cervix is the lowest part of the uterus (womb) and connects it to the upper vaginal canal. Cancers of the cervix generally develop from the lowest portion where the uterus and the vaginal canal meet. Cancers are either described as squamous, which are similar to skin cells or glandular (adenocarcinoma) which are similar to mucus secreting cells of the gastrointestinal tract. In the United States there are estimated to be over 11,000 cases diagnosed in 2007 and 3,670 women will die of the disease. Cervical cancers do not develop quickly from normal cervical cells but gradually go through a progression from a precancerous state to cancer, a process which occurs as a result of exposure to the human papillomavirus (HPV). Thankfully, only a fraction of patients with precancers of the cervix, a condition known as cervical dysplasia, develop cancer.

Q: Can cervical cancer be prevented? How?

There are two ways to prevent cervical cancer. The first is to avoid exposure to the human papillomavirus (HPV) either by not engaging in intercourse or limiting the number of partners. Condom use also reduces the risk of getting HPV. Another good way of preventing the disease is to be vaccinated to the subtypes of HPV known to cause 70% of the precancerous condition (dysplasia) and the cancer. The HPV vaccine Guardasil is now available for women 26 and under. Because cancer of the cervix generally develops slowly and progresses through a precancerous state known as dysplasia, identifying and treating precancerous changes through the use of pap testing cervical is the other way to prevent cervical cancer. Cells from the cervix can be sampled at time of pelvic exam using a pap test, which can identify precancerous cells of the cervix.

Q: How do you screen for cervical cancer?

Screening for cervical cancer is performed at the time of annual pelvic exam by using a pap test. We can sample some of the cells of the ectocervix, where these cancers generally develop and identify precancerous microscopically. This is how we identify a change before a real cancer develops. The biology of cervical cancer is that it happens to have a long (many years) precancerous phase, and that is why cervical cancer screening has been so successful

Q: What exactly is a Pap test?

A Pap test is a sampling of the cells of the cervix using a brush or small, narrow scraping paddle. It is the most effective cancer screening tool that physicians have to prevent cancer. Sampling does not harm the cervix and for women having a pelvic exam the sampling is generally not a painful process and is well tolerated. Since we have been using Pap tests, the incidence of cervical cancer has dropped dramatically. Now, with the HPV vaccine, it should go even lower.

Q: Who should get a Pap test and how often?

The general rule is that women who are sexually active or have been in the past should be screened for cervical cancer starting three years after the onset of sexually activity, or by age 21, on a yearly basis. Once a woman has a series of normal pap tests for three straight years, this testing interval can be increased. However, this should only be done after consulting with your health care provider.

Q: What is the liquid-based Pap test?

Pap tests originally were performed by smearing the cells removed from the ectocervix on a glass slide. Recent innovations have revolutionized the old pap smear and now practitioners in the U.S. generally use the new liquid-based test. This essentially replaces the glass slide. Now, the cells are taken from the brush and floated into a liquid preservative. This allows for less clumping of the cells on a slide and removes debris and mucus from the sample, which made the old pap smears harder to read. Data on this new liquid-based technology shows that it reduces the number of tests needed to be repeated due to unclear sampling and may even increase the pick-up rate of cancers and precancers. HPV testing is also done as part of the liquid pap test, which adds to our ability to decide which pap test results need treatment.

Q: Are cervical cancer vaccines approved by the FDA?

Cervical cancer vaccines are vaccines against the HPV virus sub-types that are associated with development of cervical dysplasia and cancers. The vaccine Guardasil is FDA-approved and is given as a series of three injections over six months, and ideally should be given to women prior to potential exposure to HPV, for example, before starting to have sexual intercourse. So it is currently recommended for young girls ages 9-11. However, it is FDA approved through age 26, and we are therefore doing “catch up” vaccines for young women to get them vaccinated.

Q: Who should receive the vaccine?

At this point the American Cancer Society recommends that the vaccine be given to girls age 11-12 and as early as age 9, at the discretion of a pediatrician. Older women up to age 26 should be counseled on receiving vaccination and are eligible to have catch-up vaccination. It is unclear if women older than 26 benefit from the vaccine. There is another vaccine awaiting FDA approval that will have a higher age cut-off.

Q: What is the age cut-off for receiving the vaccine?

At this point, the cut-off for receiving the vaccine is 26. Insurance will not cover the cost of the vaccine if you are older than 26.

Labels: , ,

 Subscribe to Cervical Cancer News Information Links

Sunday, April 13, 2008

Free cervical cancer screening to be offered at Southwest Virginia Cancer Center on April 19


Cedar Bluff, VA
An estimated 15 thousand new cases of cervical cancer will be diagnosed in the United States this year.

Regular testing is very important because there are no symptoms in the early stages of cervical cancer.

By undergoing an annual pelvic exam, a woman can help ensure any abnormalities are detected early.

The Southwest Virginia Cancer Center will offer free cervical screenings to area women Saturday, April 19th from 9AM - Noon.

Participants must pre-register to receive the free screening. For more information or to register, call The Wellmont Nurse Connection at 1-877-230-NURSE.

Labels: , ,

 Subscribe to Cervical Cancer News Information Links

Friday, April 11, 2008

QIAGEN focuses new HPV test ad campaign on real-life story of woman's escape from cervical cancer


Germantown, MD
Jodi McKinney, mother of five and wife of nearly 20 years, was recently diagnosed with cervical disease. Fortunately, she was able to be treated before it became cervical cancer -- thanks in part to her physician's decision to order an HPV test along with her Pap. Despite her initially normal Pap smear, the HPV test found that Jodi had a high-risk type of the human papillomavirus -- the primary cause of cervical cancer. Now, Jodi, her entire family and her physician are the focus of a new television campaign launched by QIAGEN to share what Jodi learned about cervical cancer prevention with other women across America. QIAGEN is the developer of the digene HPV Test, the only FDA-approved test for HPV.

View the entire TV ad featuring Jodi McKinney and her family sharing the message about the importance of HPV testing at http://tinyurl.com/4owquc

The ad tells of the scare first experienced by Jodi, her husband Patrick and her five children, and of the happy ending that has allowed Jodi to tell her story today. It is now being broadcast in selected cities across the country. The TV ad can be viewed online as well.
cervical cancer malpractice lawsuits

Labels: , , ,

 Subscribe to Cervical Cancer News Information Links